Keybanc Maintains Overweight on Paycom Software, Lowers Price Target to $340

Keybanc analyst Jason Celino maintains Paycom Software (NYSE:PAYC) with a Overweight and lowers the price target from $400 to $340.

byBenzinga Newsdesk

June 23, 2022

1 minute read

Keybanc analyst Jason Celino maintains Paycom Software (NYSE:PAYC) with a Overweight and lowers the price target from $400 to $340.

RBC Capital Initiates Coverage On S&P Global with Outperform Rating, Announces Price Target of $476

By Benzinga Newsdesk

Today, 6:11 AM

RBC Capital analyst Ashish Sabadra initiates coverage on S&P Global (NYSE:SPGI) with a Outperform rating and announces Price Target of $476.

SPGI

UPDATE: Aflac Q2 Adj. EPS $1.46 Beats $1.28 Estimate, Sales $5.40B Beat $4.81B Estimate

By Benzinga Newsdesk

Today, 6:11 AM

Aflac (NYSE:AFL) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of $1.28 by 14.06 percent. This is a 8.18 percent decrease over earnings of $1.59 per share from the same period

AFL

ANI Pharma Shares Quiet Amid Headline Fair Trade Commission Has Okayed Final Order Requiring ANI Pharma, Novitium Pharma To Divest Rights, Assets To Generic Sulfam

By Benzinga Newsdesk

Today, 6:11 AM

-Dow Jones

ANIP

Lexicon Pharma’s Pain Candidate Fails In Postherpetic Neuralgia Study

By Vandana Singh

Today, 6:11 AM

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced the topline results of RELIEF-PHN-1 Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia, a lasting pain in the areas of the skin that had shingles.

LXRX

Keybanc Maintains Overweight on Paycom Software, Lowers Price Target to $340

Related Posts

RBC Capital Initiates Coverage On S&P Global with Outperform Rating, Announces Price Target of $476

UPDATE: Aflac Q2 Adj. EPS $1.46 Beats $1.28 Estimate, Sales $5.40B Beat $4.81B Estimate

ANI Pharma Shares Quiet Amid Headline Fair Trade Commission Has Okayed Final Order Requiring ANI Pharma, Novitium Pharma To Divest Rights, Assets To Generic Sulfam

Lexicon Pharma’s Pain Candidate Fails In Postherpetic Neuralgia Study